Abstract
Proton pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. Medically used proton pump inhibitors are Omeprazole, Lansoprazole, Dexlansoprazole, Esomeprazole, Pantoprazole, and Rabeprazole Hence this study is planned with the aim to compare outcome of lansoprazole & rabeprozole for gastric ulcer healing in albino rats.
Total 15 albino rates were used in the study and divided in 3 groups of 5 each. The control study group and drug administered group were divided for the comparison. Aspirin was administered 200mg/kg of body weight for generation of gastric ulcers. Lansoprazole was administered 30 mg/kg of body weight and Rabeprazole was administered 20 mg/kg of body weight.
In the control group of rats the average weight of the albino rats was observed as 230 to 240 gm. In this study group ulcers percentage is 100% with the Ulcer Index as 6.2 – 6.5. In the Lansoprazole drug induced study group the weight was 245 to 256 gms. The ulcer percentage was recorded as 67% with the ulcer index in the range of 3.2 to 3.4. In the Rabeprazole drug induced patients the ulcer percentage was observed as 35% with the reduced ulcer index to 1.1-1.4 compared to previous study group rats.
Hence form the present study it can be concluded that the Rabeprazole is more effective to control the peptic ulcer than the Lansoprazole in albino rats. This study further needs to be elaborated in patients with peptic ulcer to know the actual effect and onset of action.
Keywords: Lansoprazole, rabeprozole, peptic ulcer, healing capcity, albino rats, etc.
References
1. Najm, WI (September 2011). "Peptic ulcer disease.". Primary care 38 (3): 383–94, vii. doi:10.1016/j.pop.2011.05.001. PMID 21872087.
2. Definition and Facts for Peptic Ulcer Disease". http://www.niddk.nih.gov/. Retrieved 28 February 2015.
3. Milosavljevic, T; Kostić-Milosavljević, M; Jovanović, I; Krstić, M (2011). "Complications of peptic ulcer disease.". Digestive diseases (Basel, Switzerland) 29 (5): 491–3. doi:10.1159/000331517.
4. Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet (London, England) 386 (9995): 743–800.PMID 26063472.
5. Snowden FM (October 2008). "Emerging and reemerging diseases: a historical perspective". Immunol. Rev. 225 (1): 9–26. doi:10.1111/j.1600-065X.2008. 00677.x.PMID 18837773.
6. GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014)."Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet 385: 117–71. doi:10.1016/S0140-6736(14)61682-2.
7. Wang, AY; Peura, DA (October 2011). "The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world.". Gastrointestinal endoscopy clinics of North America 21 (4): 613–35.
8. "The Nobel Prize in Physiology or Medicine 2005". nobelprize.org. Nobel Media AB. Retrieved 3 June 2015.
9. Scheeres DE, Dekryger LL; Surgical treatment of peptic ulcers before and after the introduction of H2 blockers. Primary Care, 1987;53(7):392-397.
10. Svanes C, Soreide J, Skarstein A, Fevang B, Bakke P, Vollset S, Svanes K, Soreide O; Smoking and ulcer perforation. Gut, 1997;41(2):177-180.
11. Smedley FH, Hickish P; Nonsteroidalanti inflammatory drugs and perforation. Gut; 1986;27:114-120.
12. Robinsons M (2001). New generation protonpump inhibitors: overcoming the limitations ofearly generation agents European J Gastroenterology and Hepatology; 13: S43-47.
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.225
